Lab
American Scientific Laboratory INC
American Scientific Laboratory INC was paid $24.03M by Medicaid between Jan 2018 and Dec 2024, across 112 billing codes. Its largest line is 87633, Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets — 11% of everything it billed.
33Billing provider infoAMERICAN SCIENTIFIC LABORATORY INC
NILES, IL 60714
NILES, IL 60714
33aNPI1972625499assigned 04/04/2007
33bProvider typeClinical Medical Laboratory
28Total paid$24.03M
24GClaims2,149,269
24DCodes billed112
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Illinois
Rank by total paid#7 of 235
Median peer was paid$123K
This provider vs. median196×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 258,362 | $1.98M | |
| 2019 | 344,751 | $3.01M | |
| 2020 | 280,223 | $2.37M | |
| 2021 | 249,303 | $2.67M | |
| 2022 | 362,364 | $4.19M | |
| 2023 | 426,937 | $6.14M | |
| 2024incomplete | 227,329 | $3.67M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 11% | 9,549 | 8,128 | $2.60M |
| 0223U | 6.6% | 4,324 | 2,758 | $1.59M | |
| 83970 | 4.6% | 42,991 | 37,414 | $1.11M | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.2% | 16,141 | 10,313 | $1.02M |
| 84443 | Thyroid stimulating hormone (TSH) | 3.6% | 64,045 | 54,406 | $864K |
| 86141 | 3.4% | 59,439 | 48,726 | $806K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 3.0% | 19,946 | 15,831 | $726K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.9% | 19,479 | 15,880 | $705K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.6% | 12,871 | 9,348 | $629K |
| 86038 | 2.5% | 47,225 | 38,974 | $604K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.4% | 64,224 | 51,684 | $579K |
| 86803 | 2.3% | 40,393 | 34,927 | $557K |
100 more codes
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 2.1% | 7,026 | $496K |
| 86706 | 2.0% | 43,254 | $491K | |
| 87581 | 2.0% | 14,054 | $485K | |
| 87340 | 1.9% | 42,725 | $464K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.9% | 19,600 | $456K |
| 82330 | 1.7% | 40,287 | $408K | |
| 82728 | 1.7% | 64,111 | $400K | |
| 82746 | 1.6% | 40,680 | $388K | |
| 83735 | 1.5% | 67,646 | $362K | |
| 84480 | 1.4% | 43,305 | $337K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 69,402 | $333K |
| 83540 | 1.4% | 62,566 | $327K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.3% | 7,890 | $324K |
| 84439 | 1.3% | 43,807 | $320K | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | 1.3% | 14,725 | $312K |
| 82785 | 1.3% | 45,688 | $304K | |
| 82150 | 1.3% | 58,190 | $302K | |
| 80061 | Lipid panel | 1.2% | 53,684 | $287K |
| 80053 | Comprehensive metabolic panel | 1.2% | 32,386 | $284K |
| 86063 | 1.2% | 46,106 | $281K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.1% | 51,608 | $272K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.0% | 12,028 | $242K |
| 86430 | 1.0% | 46,873 | $242K | |
| 84466 | <1% | 31,224 | $221K | |
| 86780 | <1% | 14,602 | $206K | |
| 86701 | <1% | 18,994 | $200K | |
| 99000 | <1% | 9,519 | $165K | |
| 86702 | <1% | 18,973 | $162K | |
| 86235 | <1% | 5,752 | $162K | |
| 83550 | <1% | 23,666 | $153K | |
| 84460 | <1% | 40,028 | $151K | |
| 82565 | <1% | 42,968 | $148K | |
| 82950 | <1% | 40,988 | $146K | |
| 84075 | <1% | 39,831 | $145K | |
| 84450 | <1% | 39,766 | $145K | |
| 82247 | <1% | 39,675 | $135K | |
| 82040 | <1% | 40,233 | $133K | |
| 84295 | <1% | 38,562 | $131K | |
| 82435 | <1% | 38,025 | $125K | |
| 84100 | <1% | 39,430 | $118K | |
| 84520 | <1% | 39,620 | $112K | |
| 84132 | <1% | 32,073 | $107K | |
| 84155 | <1% | 39,467 | $103K | |
| 83719 | <1% | 12,197 | $89K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 5,738 | $82K |
| 81000 | <1% | 37,987 | $81K | |
| 85651 | <1% | 16,554 | $61K | |
| 86677 | <1% | 4,648 | $60K | |
| 83718 | <1% | 10,697 | $51K | |
| 82608 | <1% | 4,742 | $50K | |
| 84550 | <1% | 14,059 | $47K | |
| 82043 | <1% | 13,336 | $44K | |
| 82378 | <1% | 3,678 | $38K | |
| 86769 | <1% | 951 | $36K | |
| 86226 | <1% | 2,911 | $34K | |
| 83690 | <1% | 5,757 | $33K | |
| 84478 | <1% | 8,098 | $31K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 261 | $31K |
| 86225 | <1% | 2,822 | $30K | |
| 86301 | <1% | 1,528 | $28K | |
| 84153 | <1% | 2,651 | $27K | |
| 86328 | <1% | 644 | $26K | |
| 84403 | <1% | 1,166 | $24K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 218 | $23K |
| 82105 | <1% | 1,663 | $23K | |
| 82465 | <1% | 8,772 | $21K | |
| 83001 | <1% | 1,300 | $20K | |
| 84234 | <1% | 568 | $18K | |
| 82570 | <1% | 4,086 | $16K | |
| 84146 | <1% | 1,231 | $14K | |
| 83002 | <1% | 1,272 | $12K | |
| 87186 | <1% | 1,039 | $11K | |
| 82533 | <1% | 883 | $10K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,145 | $10K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 218 | $9K |
| 82670 | <1% | 588 | $8K | |
| 81007 | <1% | 3,634 | $8K | |
| 84702 | <1% | 846 | $6K | |
| 82977 | <1% | 1,238 | $5K | |
| 87040 | <1% | 404 | $5K | |
| 80051 | <1% | 1,088 | $4K | |
| 83090 | <1% | 323 | $4K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 99 | $3K |
| 86592 | <1% | 825 | $3K | |
| 82140 | <1% | 434 | $3K | |
| 83615 | <1% | 800 | $3K | |
| 84484 | <1% | 355 | $2K | |
| 85660 | <1% | 513 | $2K | |
| 81001 | <1% | 809 | $2K | |
| 80050 | General health panel | <1% | 242 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 48 | $657.80 |
| 87077 | <1% | 209 | $601.75 | |
| 84144 | <1% | 52 | $455.40 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 13 | $346.42 |
| 86762 | <1% | 42 | $303.42 | |
| 84703 | <1% | 25 | $148.51 | |
| 82550 | <1% | 21 | $104.26 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,116 | $102.44 |
| 82374 | <1% | 48 | $80.26 | |
| 81025 | <1% | 13 | $25.45 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialASHFAQ, MUHAMMAD (PRESIDENT)